HOME >> BIOLOGY >> NEWS
Hepatitis B drug can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

In findings published June 21, 2007, online in the journal, the researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine. Entecavir is manufactured by Bristol-Myers Squibb and is marketed under the trade name Baraclude.

The research team was led by Chloe Thio and Howard Hughes Medical Institute investigator Robert Siliciano, both at The Johns Hopkins University School of Medicine. The analyses reported in the paper were performed by lead authors Moira McMahon, Benjamin Jilek, and Timothy Brennan in the Siliciano laboratory.

The groups initial report of the findings in February, 2007, at the Conference on Retroviruses and Opportunistic Infections led the drugs manufacturer, Bristol-Myers Squibb, to change its product labeling to warn of the potential for HIV drug resistance, notify prescribing physicians, and inform the Food and Drug Administration. The United States Department of Health and Human Services now recommends against using entecavir as the first option in treating hepatitis B in co-infected patients who are not already using drugs to suppress HIV. More than 4 million people worldwide are believed to be infected with both viruses.

The scientists emphasized that finding drug resistance in this setting underscores the need to test all antiviral drugs for anti-HIV activity before they are approved for use.

Entecavir is a chemically altered version of a chemical called a nucleoside. The drug blocks viral replication by plugging itself into a polymerase enzyme in the hepatitis B virus that helps produce new viral DNA
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
20-Jun-2007


Page: 1 2 3

Related biology news :

1. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process
2. Hepatitis E takes a piggyback
3. New hope for Hepatitis C research
4. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
5. New insights into protein synthesis and Hepatitis C infections
6. Hepatitis B accounts for 40 percent of missing Asian women
7. Hepatitis C complicated by morphine withdrawal
8. Identification of a protein important for Hepatitis B replication
9. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
10. Hepatitis C virus linked to non-Hodgkins lymphoma
11. Group decisions: From compromise to leadership in pigeon homing

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/14/2020)... ... May 12, 2020 , ... Akara ... and easily project contracted liabilities with payers, providers and pharmacies – now ... to Commercial and Government entities, Copay and Patient Assistance Program liabilities and ...
(Date:5/11/2020)... (PRWEB) , ... May 11, 2020 , ... ... remote monitoring software platform for patients with implanted cardiac devices. The Octagos software ... using one portal. The software greatly simplifies the management of remote transmissions and ...
(Date:5/1/2020)... ... April 30, 2020 , ... USARAD ... Healthineers and several healthcare VC firms announces an official launch of CareDoctors.com. In ... to enhance patient care experience by offering live video consultations with board certified ...
Breaking Biology News(10 mins):
(Date:5/5/2020)... ... May 04, 2020 , ... Red Nucleus, ... sciences industry, today announced that Informa Training Partners, a life sciences training company ... Red Nucleus Boston, effective immediately. , “The name change solidifies a stronger presence ...
(Date:5/1/2020)... YORK (PRWEB) , ... April 30, 2020 , ... ... Awards were announced today, honoring the businesses, policies, projects, and concepts that are ... a revolutionary bioprinter for living cells, which has taken out the top prize ...
(Date:4/22/2020)... Hungary and CAMBRIDGE, Mass. (PRWEB) , ... April ... ... in Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder ... led the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before ...
(Date:4/18/2020)... ... April 17, 2020 , ... NeuroFlow has ... (SBIR) program to support the expansion of its digital health platform enabling behavioral ... a rigorous merit-based review process, adds to NeuroFlow’s recent government awards . ...
Breaking Biology Technology:
Cached News: